Trial Profile
A Randomized, Open-label, Single-dose, Dose-escalation, Self-controlled Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YPEG-Filgrastim in Cancer Patients Receiving Chemotherapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Jun 2014
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Neutropenia
- Focus Pharmacodynamics
- Sponsors Xiamen Amoytop Biotech
- 19 Jun 2014 New trial record